SCHEMBL402033

SCHEMBL402033

CCOC(=O)c1cc(Br)c(C)[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 4/20 0.50
HPGD P15428 4/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
HSD17B10 Q99714 1/20 0.50
MAPT P10636 4/20 0.49
LMNA P02545 4/20 0.49
NPC1 O15118 3/20 0.49
KMT2A Q03164 2/20 0.49
GAA P10253 2/20 0.49
PKM P14618 1/20 0.49
MEN1 O00255 1/20 0.49
GLA P06280 1/20 0.49
ATM Q13315 1/20 0.49
ALOX15 P16050 1/20 0.48
L3MBTL1 Q9Y468 3/20 0.47
HTT P42858 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
MMP13 P45452 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5747195 0.89 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL23421678 0.86 HRH3 (0.46) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL21126993 0.86 MAP2K1 (0.52) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL3282478 0.83 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL17130065 0.81 XDH (0.57) ALDH1A1KDM4ERAB9AMAPTKMT2A
SCHEMBL2150729 0.81 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL27034946 0.81 HRH3 (0.50) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL16569634 0.80 ALDH1A1 (0.48) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL5077719 0.80 KDM4E (0.47) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL14270035 0.80 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651953-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2025-11-26 EP disclosed
EP-4651951-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2025-11-26 EP disclosed
EP-4651948-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2025-11-26 EP disclosed
EP-4651946-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2025-11-26 EP disclosed
WO-2024182715-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2024-09-06 WO disclosed
WO-2024155837-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2024-07-25 WO disclosed
WO-2024155840-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2024-07-25 WO disclosed
WO-2024155846-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2024-07-25 WO disclosed
WO-2024155847-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2024-07-25 WO disclosed
WO-2024091370-A1 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2024-05-02 WO disclosed
US-20100179150-A1 ANTIBACTERIAL PIPERDINE DERIVATIVES ASTRAZENECA AB (SE) 2010-07-15 US disclosed
WO-2010067125-A1 2- (PIPERIDIN-1-YL) -4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2010-06-17 WO disclosed
WO-2010067125-A1 2- (PIPERIDIN-1-YL) -4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2010-06-17 WO disclosed
US-7709503-B2 Pyrrol derivatives with antibacterial activity ASTRAZENECA AB (SE) 2010-05-04 US disclosed
EP-1853586-A1 ANTIBACTERIAL PIPERIDINE DERIVATIVES AstraZeneca AB (SE) 2007-11-14 EP disclosed
EP-1664025-B1 PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2007-09-19 EP disclosed
US-20060223801-A1 Pyrrol derivatives with antibacterial activity ASTRAZENECA AB (SE) 2006-10-05 US disclosed
WO-2006087543-A1 ANTIBACTERIAL PIPERIDINE DERIVATIVES ASTRAZENECA AB (SE) 2006-08-24 WO disclosed
EP-1664025-A1 PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY AstraZeneca AB (SE) 2006-06-07 EP disclosed
WO-2005026149-A1 PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223801-A1 Pyrrol derivatives with antibacterial activity PEF1, PEPD, PELP1 ALDH1A1 976/4885KDM4E 3380/4885HPGD 356/4885
US-20100179150-A1 ANTIBACTERIAL PIPERDINE DERIVATIVES PIR, HAMP, AMPD2 ALDH1A1 502/4885KDM4E 3484/4885HPGD 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.